Compositions and methods for treating alzheimer's disease
US-2024376452-A1 · Nov 14, 2024 · US
Compositions and methods for silencing hepatitis B virus gene expression
US10415037B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10415037-B2 |
| Application number | US-201515515952-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 1, 2015 |
| Priority date | Oct 2, 2014 |
| Publication date | Sep 17, 2019 |
| Grant date | Sep 17, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compositions comprising therapeutic nucleic acids such as siRNA that target Hepatitis B virus (HBV) gene expression, lipid particles comprising one or more (e.g., a combination) of the therapeutic nucleic acids, and methods of delivering and/or administering the lipid particles (e.g., for treating HBV infection and/or HDV infection in humans).
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated, modified, nucleic acid molecule selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27 and SEQ ID NO:29. 2. An isolated, modified, nucleic acid molecule selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:26, SEQ ID NO:28 and SEQ ID NO:30. 3. An isolated, modified, double stranded, siRNA molecule selected from the group consisting of 1m (SEQ ID NO:1 and 2), 2m (SEQ ID NO:3 and 4), 3m (SEQ ID NO:5 and 6), 4m (SEQ ID NO:7 and 8), 5m (SEQ ID NO:9 and 10), 6m (SEQ ID NO:11 and 12), 7m (SEQ ID NO:13 and 14), 8m (SEQ ID NO:15 and 16), 9m (SEQ ID NO:17 and 18), 10m (SEQ ID NO:19 and 20), 11m (SEQ ID NO:21 and 22), 12m (SEQ ID NO:23 and 24), 13m (SEQ ID NO:25 and 26), 14m (SEQ ID NO:27 and 28) and 15m (SEQ ID NO:29 and 30). 4. A composition comprising an isolated, double stranded siRNA molecule of claim 3 . 5. The composition of claim 4 comprising two different double stranded siRNA molecules selected from the group consisting of 1m (SEQ ID NO:1 and 2), 2m (SEQ ID NO:3 and 4), 3m (SEQ ID NO:5 and 6), 4m (SEQ ID NO:7 and 8), 5m (SEQ ID NO:9 and 10), 6m (SEQ ID NO:11 and 12), 7m (SEQ ID NO:13 and 14), 8m (SEQ ID NO:15 and 16), 9m (SEQ ID NO:17 and 18), 10m (SEQ ID NO:19 and 20), 11m (SEQ ID NO:21 and 22), 12m (SEQ ID NO:23 and 24), 13m (SEQ ID NO:25 and 26), 14m (SEQ ID NO:27 and 28) and 15m (SEQ ID NO:29 and 30). 6. The composition of claim 5 , wherein a combination of the two different double stranded siRNA molecules is 1m-2m;1m-3m;1m-4m;1m-5m;1m-6m;1m-7m;1m-8m;1m-9m;1m-10m;1m-11m;1m-12m;1m-13m;1m-14m;1m-15m;2m-3m;2m-4m;2m-5m;2m-6m;2m-7m;2m-8m;2m-9m;2m-10m;2m-11 m;2m-12m;2m-13m;2m-14m;2m-15m;3m-4m;3m-5m;3m-6m;3m-7m;3m-8m;3m-9m;3m-10m;3m-11m;3m-12m;3m-13m;3m-14m;3m-15m;4m-5m;4m-6m;4m-7m;4m-8m;4m-9m;4m-10m;4m-11m;4m-12m;4m-13m;4m-14m;4m-15m;5m-6m;5m-7m;5m-8m;5m-9m;5m-10m;5m-11m;5m-12m;5m-13m;5m-14m;5m-15m;6m-7m;6m-8m;6m-9m;6m-10m;6m-111m;6m-12m;6m-13m;6m-14m;6m-15m;7m-8m;7m-9m;7m-10m; 7m-11;7m-12m;7m-13m;7m-14m;7m-15m;8m-9m;8m-10m;8m-111m;8m-12m;8m-13m;8m-14m;8m-15m;9m-10m;9m-11m;9m-12m;9m-13m;9m-14m;9m-15m;10m-11m;10m-12m;10m-13m;10m-14m;10m-15m;11m-12m;11 m-13m;11 m-14m;11m-15m;12m-13m;12m-14m;12m-15m;13m-14m;13m-15m; or 14m-15m. 7. The composition of claim 4 comprising three different double stranded siRNA molecules selected from the group consisting of 1m (SEQ ID NO:1 and 2), 2m (SEQ ID NO:3 and 4), 3m (SEQ ID NO:5 and 6), 4m (SEQ ID NO:7 and 8), 5m (SEQ ID NO:9 and 10), 6m (SEQ ID NO:11 and 12), 7m (SEQ ID NO:13 and 14), 8m (SEQ ID NO:15 and 16), 9m (SEQ ID NO:17 and 18), 10m (SEQ ID NO:19 and 20), 11m (SEQ ID NO:21 and 22), 12m (SEQ ID NO:23 and 24), 13m (SEQ ID NO:25 and 26), 14m (SEQ ID NO:27 and 28) and 15m (SEQ ID NO:29 and 30). 8. The composition of claim 7 , wherein a combination of the three different double stranded siRNA molecules is 1m-2m-3m;1m-2m-4m;1m-2m-5m;1m-2m-6m;1m-2m-7m;1m-2m-8m;1m-2m-9m;1m-2m-10m;1m-2m-11m;1m-2m-12m;1m-2m-13m;1m-2m-14m;1m-2m-15m;1m-3m-4m;1m-3m-5m;1m-3m-6m;1m-3m-7m;1m-3m-8m;1m-3m-9m;1m-3m-10m;1m-3m-111m;1m-3m-12m;1m-3m-13m;1m-3m-14m;1m-3m-15m;1m-4m-5m;1m-4m-6m;1m-4m-7m;1m-4m-8m;1m-4m-9m;1m-4m-10m;1m-4m-11m;1m-4m-12m;1m-4m-13m;1m-4m-14m;1m-4m-15m;1m-5m-6m;1m-5m-7m;1m-5m-8m;1m-5m-9m;1m-5m-10m;1m-5m-11;1m-5m-12m;1m-5m-13m;1m-5m-14m;1m-5m-15m;1m-6m-7m;1m-6m-8m;1m-6m-9m;1m-6m-10m;1m-6m-11m;1m-6m-12m;1m-6m-13m;1m-6m-14m;1m-6m-15m;1m-7m-8m;1m-7m-9m;1m-7m-10m;1m-7m-11m;1m-7m-12m;1m-7m-13m;1m-7m-14m;1m-7m-15m;1m-8m-9m;1m-8m-10m;1m-8m-11m;1m-8m-12m;1m-8m-13m;1m-8m-14m;1m-8m-15m;1m-9m-10m;1m-9m-11m;1m-9m-12m;1m-9m-13m;1m-9m-14m;1m-9m-15m;1m-10m-11m;1m-10m-12m;1m-10m-13m;1m-10m-14m;1m-10m-15m;1m-11m-12m;1m-11m-13m;1m-11m-14m;1m-11m-15m;1m-12m-13m;1m-12m-14m;1m-12m-15m;1m-13m-14m;1m-13m-15m;1m-14m-15m;2m-3m-4m;2m-3m-5m;2m-3m-6m;2m-3m-7m;2m-3m-8m;2m-3m-9m;2m-3m-10m;2m-3m-11m;2m-3m-12m;2m-3m-13m;2m-3m-14m;2m-3m-15m;2m-4m-5m;2m-4m-6m;2m-4m-7m;2m-4m-8m;2m-4m-9m;2m-4m-10m;2m-4m-11m;2m-4m-12m;2m-4m-13m;2m-4m-14m;2m-4m-15m;2m-5m-6m;2m-5m-7m;2m-5m-8m;2m-5m-9m;2m-5m-10m;2m-5m-11m;2m-5m-12m;2m-5m-13m;2m-5m-14m;2m-5m-15m;2m-6m-7m;2m-6m-8m;2m-6m-9m;2m-6m-10m;2m-6m-11m;2m-6m-12m;2m-6m-13m;2m-6m-14m;2m-6m-15m;2m-7m-8m;2m-7m-9m;2m-7m-10m;2m-7m-11m;2m-7m-12m;2m-7m-13m;2m-7m-14m;2m-7m-15m;2m-8m-9m;2m-8m-10m;2m-8m-11m;2m-8m-12m;2m-8m-13m;2m-8m-14m;2m-8m-15m;2m-9m-10m;2m-9m-11m;2m-9m-12m;2m-9m-13m;2m-9m-14m;2m-9m-15m;2m-10m-11m;2m-10m-12m;2m-10m-13m;2m-10m-14m;2m-10m-15m;2m-11m-12m;2m-11m-13m;2m-11m-14m;2m-11m-15m;2m-12m-13m;2m-12m-14m;2m-12m-15m;2m-13m-14m;2m-13m-15m;2m-14m-15m;3m-4m-5m;3m-4m-6m;3m-4m-7m;3m-4m-8m;3m-4m-9m;3m-4m-10m;3m-4m-11m;3m-4m-12m;3m-4m-13m;3m-4m-14m;3m-4m-15m;3m-5m-6m;3m-5m-7m;3m-5m-8m;3m-5m-9m;3m-5m-10m;3m-5m-111m;3m-5m-12m;3m-5m-13m;3m-5m-14m;3m-5m-15m;3m-6m-7m;3m-6m-8m;3m-6m-9m;3m-6m-10m;3m-6m-11m;3m-6m-12m;3m-6m-13m;3m-6m-14m;3m-6m-15m;3m-7m-8m;3m-7m-9m;3m-7m-10m;3m-7m-11m;3m-7m-12m;3m-7m-13m;3m-7m-14m;3m-7m-15m;3m-8m-9m;3m-8m-10m;3m-8m-11m;3m-8m-12m;3m-8m-13m;3m-8m-14m;3m-8m-15m;3m-9m-10m;3m-9m-111m;3m-9m-12m;3m-9m-13m;3m-9m-14m;3m-9m-15m;3m-10m-11m;3m-10m-12m;3m-10m-13m;3m-10m-14m;3m-10m-15m;3m-11m-12m;3m-11m-13m;3m-11m-14m;3m-11m-15m;3m-12m-13m;3m-12m-14m;3m-12m-15m;3m-13m-14m;3m-13m-15m;3m-14m-15m;4m-5m-6m;4m-5m-7m;4m-5m-8m;4m-5m-9m;4m-5m-10m;4m-5m-11m;4m-5m-12m;4m-5m-13m;4m-5m-14m;4m-5m-15m;4m-6m-7m;4m-6m-8m;4m-6m-9m;4m-6m-10m;4m-6m-11m;4m-6m-12m;4m-6m-13m;4m-6m-14m;4m-6m-15m;4m-7m-8m;4m-7m-9m;4m-7m-10m;4m-7m-11m;4m-7m-12m;4m-7m-13m;4m-7m-14m;4m-7m-15m;4m-8m-9m;4m-8m-10m;4m-8m-11m;4m-8m-12m;4m-8m-13m;4m-8m-14m;4m-8m-15m;4m-9m-10m;4m-9m-11m;4m-9m-12m;4m-9m-13m;4m-9m-14m;4m-9m-15m;4m-10m-11m;4m-10m-12m;4m-10m-13m;4m-10m-14m;4m-10m-15m;4m-11m-12m;4m-11m-13m;4m-11m-14m;4m-11m-15m;4m-12m-13m;4m-12m-14m;4m-12m-15m;4m-13m-14m;4m-13m-15m;4m-14m-15m;5m-6m-7m;5m-6m-8m;5m-6m-9m;5m-6m-10m;5m-6m-11m;5m-6m-12m;5m-6m-13m;5m-6m-14m;5m-6m-15m;5m-7m-8m;5m-7m-9m;5m-7m-10m;5m-7m-11m;5m-7m-12m;5m-7m-13m;5m-7m-14m;5m-7m-15m;5m-8m-9m;5m-8m-10m;5m-8m-11m;5m-8m-12m;5m-8m-13m;5m-8m-14m;5m-8m-15m;5m-9m-10m;5m-9m-11m;5m-9m-12m;5m-9m-13m;5m-9m-14m;5m-9m-15m;5m-10m-11m;5m-10m-12m;5m-10m-13m;5m-10m-14m;5m-10m-15m;5m-11m-12m;5m-11m-13m;5m-11m-14m;5m-11m-15m;5m-12m-13m;5m-12m-14m;5m-12m-15m;5m-13m-14m;5m-13m-15m;5m-14m-15m;6m-7m-8m;6m-7m-9m;6m-7m-10m;6m-7m-11m;6m-7m-12m;6m-7m-13m;6m-7m-14m;6m-7m-15m;6m-8m-9m;6m-8m-10m;6m-8m-11m;6m-8m-12m;6m-8m-13m;6m-8m-14m;6m-8m-15m;6m-9m-10m;6m-9m-11m;6m-9m-12m;6m-9m-13m;6m-9m-14m;6m-9m-15m;6m-10m-11m;6m-10m-12m;6m-10m-13m;6m-10m-14m;6m-10m-15m;6m-11m-12m;6m-11m-13m;6m-11m-14m;6m-11m-15m;6m-12m-13m;6m-12m-14m;6m-12m-15m;6m-13m-14m;6m-13m-15m;6m-14m-15m;7m-8m-9m;7m-8m-10m;7m-8m-11m;7m-8m-12m;7m-8m-13m;7m-8m-14m;7m-8m-15m;7m-9m-10m;7m-9m-11m;7m-9m-12m;7m-9m-13m;7m-9m-14m;7m-9m-15m;7m-10m-11m;7m-10m-12m;7m-10m-13m;7m-10m-14m;7m-10m-15m;7m-11m-12m;7m-11m-13m;7m-11m-14m;7m-11m-15m;7m-12m-13m;7m-12m-14m;7m-12m-15m;7m-13m-14m;7m-13m-15m;7m-14m-15m;8m-9m-10m;8m-9m-11m;8m-9m-12m;8m-9m-13m;8m-9m-14m;8m-9m-15m;8m-10m-11m;8m-10m-12m;8m-10m-13m;8m-10m-14m;8m-10m-15m;8m-11m-12m;8m-11m-13m;8m-11-m14m;8m-11m-15m;8m-12m-13m;8m-12m-14m;8m-12m-15m;8m-13m-14m;8m-13m-15m;8m-14m-15m;9m-10m-11m;9m-10m-12m;9m-10m-13m;9m-10m-14m;9m-10m-15m;9m-11m-12m;9m-11m-13m;9m-11m-14m;9m-11m-15m;9m-12m-13m;9m-12m-14m;9m-12m-15m;9m-13m-14m;9m-13m-15m;9m-14m-15m;10m-11m-12m;10m-11m-13m;10m-11m-14m;10m-11m-15m;10m-12m-13m;10m-12m-14m;10m-12m-15m;10m-13m-14m;10m-13m-15m;10m-14m-15m;11m-12m-13m;11m-12m-14m;11m-12m-15m;11m-13m-14m;11m-13m-15m;11m-14m-15m;12m-13m-14m;12m-13m-15m;12m-14m-15m; or 13m-14m-15m. 9. A nucleic acid-lipid particle comprisi
Assignees
Inventors
Classifications
for DNA viruses · CPC title
for RNA viruses · CPC title
modified ring structure · CPC title
- C12N15/1131Primary
against viruses · CPC title
interfering nucleic acids [NA] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10415037B2 cover?
- The present invention provides compositions comprising therapeutic nucleic acids such as siRNA that target Hepatitis B virus (HBV) gene expression, lipid particles comprising one or more (e.g., a combination) of the therapeutic nucleic acids, and methods of delivering and/or administering the lipid particles (e.g., for treating HBV infection and/or HDV infection in humans).
- Who is the assignee on this patent?
- Arbutus Biopharma Corp
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1131. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).